All In Biotech

Drug Trial Radar · NCT01572792

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Apr 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 921 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

921

Actual

Start

Apr 2012

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). Long-term efficacy, pharmacoeconomic and health-related quality of life assessments will also be evaluated. This extension study will include a 28 week treatment period, followed by a four week follow up visit. All patients will remain in the same treatment group as for the lead-in study and continue on one of the four treatment arms or placebo.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)Drug

    Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose, twice per day

  • Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)Drug

    Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose, twice per day

  • Aclidinium bromideDrug

    Inhaled Aclidinium bromide 400 μg, twice per day

  • Formoterol FumarateDrug

    Inhaled Formoterol Fumarate 12 μg, twice per day

  • PlaceboDrug

    Inhaled dose-matched placebo, twice per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients to Experience Any Treatment-emergent Adverse EventTime frame: Baseline of lead-in study to follow-up call 14±3 days after last dose of investigational product (up to Week 52)

Locations

208 sites in 4 countries. Site status is shown where the registry gives one.

  • Forest Investigative Site 1827

    Anniston, Alabama

  • Forest Investigative Site 1920

    Athens, Alabama

  • Forest Investigative Site 1162

    Birmingham, Alabama

  • Forest Investigative Site 1493

    Birmingham, Alabama

  • Forest Investigative Site 1937

    Birmingham, Alabama

  • Forest Investigative Site 1824

    Gulf Shores, Alabama

  • Forest Investigative Site 2088

    Jasper, Alabama

  • Forest Investigative Site 1918

    Scottsboro, Alabama

  • Forest Investigative Site 0909

    Glendale, Arizona

  • Forest Investigative Site 1379

    Phoenix, Arizona

  • Forest Investigative Site 1822

    Anaheim, California

  • Forest Investigative Site 1483

    Buena Park, California

  • Forest Investigative Site 1156

    Fresno, California

  • Forest Investigative Site 1871

    Lincoln, California

  • Forest Investigative Site 1873

    Los Angeles, California

  • Forest Investigative Site 2064

    Riverside, California

  • Forest Investigative Site 1427

    Sacramento, California

  • Forest Investigative Site 1866

    Sacramento, California

  • Forest Investigative Site 1125

    San Diego, California

  • Forest Investigative Site 2009

    San Diego, California

  • Forest Investigative Site 1374

    Torrance, California

  • Forest Investigative Site 1813

    Tustin, California

  • Forest Investigative Site 1883

    Vista, California

  • Forest Investigative Site 1380

    Golden, Colorado

  • Forest Investigative Site 1137

    Pueblo, Colorado

  • Forest Investigative Site 1327

    Wheat Ridge, Colorado

  • Forest Investigative Site 1976

    Waterbury, Connecticut

  • Forest Investigative Site 1821

    Bay Pines, Florida

  • Forest Investigative Site 1154

    Brandon, Florida

  • Forest Investigative Site 1944

    Brandon, Florida

  • Forest Investigative Site 1364

    Clearwater, Florida

  • Forest Investigative Site 1152

    Clearwater, Florida

  • Forest Investigative Site 1875

    Clearwater, Florida

  • Forest Investigative Site 1811

    Covington, Florida

  • Forest Investigative Site 0670

    DeLand, Florida

  • Forest Investigative Site 1516

    Edgewater, Florida

  • Forest Investigative Site 0990

    Fort Lauderdale, Florida

  • Forest Investigative Site 1513

    Hialeah, Florida

  • Forest Investigative Site 1854

    Hialeah, Florida

  • Forest Investigative Site 1882

    Hollywood, Florida

Showing 40 of 208 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.